Recently, an innovative strategy based on a liposome loaded with the BCL2 inhibitor (venetoclax) using an anti-CD26 antibody (begelomab) to selectively target CML LSCs showed that the immunoliposome could reduce cell growth and also induce apoptosis in CD26+ LSCs, along with synergistic effects by coadministration with imatinib or nilotinib [210]. Here, DPP4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.